ECSP13012653A - COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER - Google Patents

COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER

Info

Publication number
ECSP13012653A
ECSP13012653A ECSP13012653A ECSP13012653A EC SP13012653 A ECSP13012653 A EC SP13012653A EC SP13012653 A ECSP13012653 A EC SP13012653A EC SP13012653 A ECSP13012653 A EC SP13012653A
Authority
EC
Ecuador
Prior art keywords
piridin
ilo
cancer treatment
oxazol
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
De La Nava Eva Maria Martin
David Andrew Coates
Raymond Gilmour
Jose Alfredo Martin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012653(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP13012653A publication Critical patent/ECSP13012653A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

1. Un compuesto de la fórmulacaracterizado porqueX es metoxietilo o etoximetilo;Q es ciclopropilo, 2-metil-propanol-2-ilo, 3-metiloxetan-3-ilo, 1-hidroximetil-1-ciclopropilo; o una sal del mismo farmacéuticamente aceptable.
ECSP13012653 2010-12-03 2013-05-31 COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER ECSP13012653A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382329 2010-12-03
US201161439151P 2011-02-03 2011-02-03

Publications (1)

Publication Number Publication Date
ECSP13012653A true ECSP13012653A (es) 2013-08-30

Family

ID=46162794

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012653 ECSP13012653A (es) 2010-12-03 2013-05-31 COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER

Country Status (26)

Country Link
US (1) US8288548B2 (es)
EP (1) EP2646445B1 (es)
JP (1) JP5726321B2 (es)
KR (1) KR101514162B1 (es)
CN (1) CN103221415B (es)
AR (1) AR083868A1 (es)
AU (1) AU2011337033A1 (es)
BR (1) BR112013013282A2 (es)
CA (1) CA2819822C (es)
CL (1) CL2013001518A1 (es)
CO (1) CO6761387A2 (es)
CR (1) CR20130182A (es)
DO (1) DOP2013000116A (es)
EA (1) EA021241B1 (es)
EC (1) ECSP13012653A (es)
ES (1) ES2567271T3 (es)
GT (1) GT201300139A (es)
IL (1) IL226054A0 (es)
MX (1) MX2013006184A (es)
NZ (1) NZ610289A (es)
PE (1) PE20140008A1 (es)
SG (1) SG190680A1 (es)
TW (1) TWI410425B (es)
UA (1) UA109677C2 (es)
WO (1) WO2012074761A1 (es)
ZA (1) ZA201303580B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
ES2251582T3 (es) * 2001-03-09 2006-05-01 Pfizer Products Inc. Compuestos antiinflamatorios de bencimidazol.
AU2003256297A1 (en) * 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
AU2005251735A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use

Also Published As

Publication number Publication date
WO2012074761A1 (en) 2012-06-07
CA2819822A1 (en) 2012-06-07
KR20130093140A (ko) 2013-08-21
ZA201303580B (en) 2014-12-23
IL226054A0 (en) 2013-06-27
EP2646445B1 (en) 2016-03-16
CR20130182A (es) 2013-07-09
JP2013544835A (ja) 2013-12-19
PE20140008A1 (es) 2014-01-31
KR101514162B1 (ko) 2015-04-21
CN103221415B (zh) 2015-06-17
CL2013001518A1 (es) 2013-11-04
EA021241B1 (ru) 2015-05-29
AR083868A1 (es) 2013-03-27
JP5726321B2 (ja) 2015-05-27
CO6761387A2 (es) 2013-09-30
TW201300397A (zh) 2013-01-01
US20120142724A1 (en) 2012-06-07
EA201390620A1 (ru) 2013-10-30
BR112013013282A2 (pt) 2016-09-06
US8288548B2 (en) 2012-10-16
NZ610289A (en) 2015-07-31
MX2013006184A (es) 2013-07-15
DOP2013000116A (es) 2014-10-31
ES2567271T3 (es) 2016-04-21
GT201300139A (es) 2014-04-08
SG190680A1 (en) 2013-07-31
CN103221415A (zh) 2013-07-24
UA109677C2 (ru) 2015-09-25
EP2646445A1 (en) 2013-10-09
AU2011337033A1 (en) 2013-07-18
CA2819822C (en) 2015-07-21
TWI410425B (zh) 2013-10-01

Similar Documents

Publication Publication Date Title
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR077629A1 (es) Mimetico de smac
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
SV2009003390A (es) Uso de compuestos inhibidores de quinaxolina de p13k- alfa para el tratamiento del cancer
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
PE20191655A1 (es) Combinaciones farmaceuticas
AR103680A1 (es) Inhibidores selectivos de bace1
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
WO2012078902A3 (en) Proteostasis regulators
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
EA201591024A1 (ru) Димерные соединения
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
MX340574B (es) Imidazo pirazinas.
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
MX2014006686A (es) Derivaods novedosos de pirrol.